Our technology relies on LeaLing Bio’s leading expertise in the fields of T-cell biology and antibody engineering to discover and develop next-generation antibody-based therapeutics
LeaLing’s Proprietary Technological Platforms:
- LeaMab: common-light-chain+sdAb to generate BIC trispecific antibodies
- LeaTCR: TCR and TCR mimic based T cell engagers
- LeaBody: next generation costimulatory T cell engager platform
- Novel target identification platform: scRNA and scTCR/BCR sequencing based database
Targeted antibody delivery platform: LNP-mRNA platform
